Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Protara Therapeutics
AstraZeneca
Relmada Therapeutics, Inc.
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AstraZeneca
NRG Oncology
Memorial Sloan Kettering Cancer Center
Pfizer
Janssen Research & Development, LLC
UroGen Pharma Ltd.
CG Oncology, Inc.
Astellas Pharma Inc
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
AstraZeneca
University of Pittsburgh
Centre Hospitalier Universitaire Vaudois
Bristol-Myers Squibb
Sahlgrenska University Hospital
Merck Sharp & Dohme LLC
Ferring Pharmaceuticals
University of Rome Tor Vergata
University Health Network, Toronto
SWOG Cancer Research Network
Regina Elena Cancer Institute
Hoffmann-La Roche
Verity Pharmaceuticals Inc.
Tata Memorial Centre
University of Campinas, Brazil
Merck Sharp & Dohme LLC
Sun Yat-sen University
UroGen Pharma Ltd.
Photocure
UroGen Pharma Ltd.
Assiut University
UroGen Pharma Ltd.
Fujian Medical University Union Hospital
Second Xiangya Hospital of Central South University
Pfizer
Memorial Sloan Kettering Cancer Center
Chengdu CoenBiotech Co., Ltd
Brigham and Women's Hospital
Eli Lilly and Company
Canadian Cancer Trials Group